This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robson, M. Articles by Offit, K. Search for Related Content PubMed PubMed Citation Articles by Robson, M. Articles by Offit, K.

BRCA-associated Breast Cancer: Absence of a Characteristic Immunophenotype¹

Departments of Human Genetics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

To characterize the biological features of breast cancer associated with germ-line mutations in BRCA1 and BRCA2, invasive tumors were studied from 58 Jewish women ascertained through studies of early-onset breast cancer. All women were tested for the BRCA1 founder mutations 187delAG (commonly known as 185delAG) and 5385insC (commonly known as 5382insC) and the BRCA2 founder mutation 6174delT. Mutations were detected in 17 of 58 (29.3%) women. Comparing BRCA-associated breast cancers (BABCs) to cases arising in women without founder mutations, no differences were noted in tumor size, tumor stage, or frequency of axillary nodal involvement. Infiltrating ductal carcinoma was the predominant histological type in both groups. BABCs were significantly more likely to be of histological grade III (100 versus 63%; P = 0.04), estrogen receptor negative (75 versus 35%; P = 0.004), and HER2/neu negative (87 versus 58%; P = 0.04). An associated intraductal component was present in 59% of BABCs and 76% of cancers not associated with mutations (P = not significant). A high Ki-67 labeling index was more commonly observed in BABCs than in cases without mutations (83 versus 48%; P = 0.09). There were no differences between the two groups in the frequency of expression of epidermal growth factor receptor, cathepsin D, bcl-2, p27, p53, or cyclin D. There were no significant differences in relapse-free or overall survival.

These observations suggest that breast cancers arising in Jewish women with germ-line BRCA founder mutations have a greater proliferative potential than cancers in women without such mutations. Additional studies of BABC are required to determine the nature and implications of additional genetic abnormalities occurring in these tumors.

¹ Supported in part by Specialized Program of Research Excellence Grant P50 CA94027 from the National Cancer Institute. M. R. is supported by American Cancer Society Physician's Research Training Award PRTA-38.

² To whom requests for reprints should be addressed, at Clinical Genetics Service, Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: robsonm@mskcc.org.

Received 10/21/97. Accepted 2/27/98.

This article has been cited by other articles:

				C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma J. Clin. Oncol., January 20, 2009; 27(3): 433 - 438. [Abstract] [Full Text] [PDF]

				D. P. Atchley, C. T. Albarracin, A. Lopez, V. Valero, C. I. Amos, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and B. K. Arun Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer J. Clin. Oncol., September 10, 2008; 26(26): 4282 - 4288. [Abstract] [Full Text] [PDF]

				P van der Groep, A Bouter, R van der Zanden, I Siccama, F H Menko, J J P Gille, C van Kalken, E van der Wall, R H M Verheijen, and P J van Diest Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data J. Clin. Pathol., June 1, 2006; 59(6): 611 - 617. [Abstract] [Full Text] [PDF]

				B G Haffty, A Silber, E Matloff, J Chung, and D Lannin Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women J. Med. Genet., February 1, 2006; 43(2): 133 - 137. [Abstract] [Full Text] [PDF]

				S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]

				T. A. King, M. L. Gemignani, W. Li, D. D. Giri, K. S. Panageas, F. Bogomolniy, C. Arroyo, N. Olvera, M. E. Robson, K. Offit, et al. Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers Cancer Res., August 1, 2004; 64(15): 5051 - 5053. [Abstract] [Full Text] [PDF]

				W. D. Foulkes, K. Metcalfe, P. Sun, W. M. Hanna, H. T. Lynch, P. Ghadirian, N. Tung, O. I. Olopade, B. L. Weber, J. McLennan, et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer: The Influence of Age, Grade, and Histological Type Clin. Cancer Res., March 15, 2004; 10(6): 2029 - 2034. [Abstract] [Full Text] [PDF]

				L. F. A. Wessels, T. van Welsem, A. A. M. Hart, L. J. van't Veer, M. J. T. Reinders, and P. M. Nederlof Molecular Classification of Breast Carcinomas by Comparative Genomic Hybridization: a Specific Somatic Genetic Profile for BRCA1 Tumors Cancer Res., December 1, 2002; 62(23): 7110 - 7117. [Abstract] [Full Text] [PDF]

				C. Kennedy, K. Byth, C. L. Clarke, and A. deFazio Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate Mol. Cancer Ther., October 1, 2002; 1(12): 1025 - 1033. [Abstract] [Full Text] [PDF]

				T. A. Grushko, M. A. Blackwood, P. L. Schumm, F. G. Hagos, M. O. Adeyanju, M. D. Feldman, M. O. Sanders, B. L. Weber, and O. I. Olopade Molecular-Cytogenetic Analysis of HER-2/neu Gene in BRCA1-associated Breast Cancers Cancer Res., March 1, 2002; 62(5): 1481 - 1488. [Abstract] [Full Text] [PDF]

				S R Lakhani Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer Mol. Pathol., October 1, 2001; 54(5): 281 - 284. [Abstract] [Full Text] [PDF]

				S A J Vaziri, R R Tubbs, G Darlington, and G Casey Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol. Pathol., August 1, 2001; 54(4): 259 - 263. [Abstract] [Full Text] [PDF]

				S. A. J. Vaziri, L. M. Krumroy, P. Elson, G. T. Budd, G. Darlington, J. Myles, R. R. Tubbs, and G. Casey Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis Clin. Cancer Res., July 1, 2001; 7(7): 1937 - 1945. [Abstract] [Full Text] [PDF]

				P. O. Chappuis, L. Kapusta, L. R. Begin, N. Wong, J.-S. Brunet, S. A. Narod, J. Slingerland, and W. D. Foulkes Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer J. Clin. Oncol., December 15, 2000; 18(24): 4045 - 4052. [Abstract] [Full Text] [PDF]

				L. C. Verhoog, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, and J. G. M. Klijn Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients J. Clin. Oncol., November 1, 2000; 18(90001): 119s - 124. [Abstract] [Full Text] [PDF]

				M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy, A. Heerdt, P. Borgen, B. McCormick, C. Hudis, L. Norton, et al. Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations J Natl Cancer Inst, December 15, 1999; 91(24): 2112 - 2117. [Abstract] [Full Text] [PDF]

				L. C. Verhoog, C.T.M. Brekelmans, C. Seynaeve, G. Dahmen, A. N. van Geel, C.C.M. Bartels, M.M.A. Tilanus-Linthorst, A. Wagner, P. Devilee, D.J.J. Halley, et al. Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2 J. Clin. Oncol., November 1, 1999; 17(11): 3396 - 3402. [Abstract] [Full Text] [PDF]

				K.-A. Phillips, I. L. Andrulis, and P. J. Goodwin Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different? J. Clin. Oncol., November 1, 1999; 17(11): 3653 - 3663. [Abstract] [Full Text] [PDF]

				J. E. Armes, L. Trute, D. White, M. C. Southey, F. Hammet, A. Tesoriero, A.-M. Hutchins, G. S. Dite, M. R. E. McCredie, G. G. Giles, et al. Distinct Molecular Pathogeneses of Early-Onset Breast Cancers in BRCA1 and BRCA2 Mutation Carriers: A Population-based Study Cancer Res., April 1, 1999; 59(8): 2011 - 2017. [Abstract] [Full Text] [PDF]